Current Report Filing (8-k)
20 June 2018 - 7:22AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 19, 2018 (June 18, 2018)
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
001-36268
|
|
22-2983783
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
File
Number)
|
|
Identification
Number)
|
201
Grove Road
Thorofare,
New Jersey USA 08086
(Address
of principal executive offices, including zip code)
(856)
848-8698
(Registrant’s
telephone number, including area code)
Check
thebelow if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
4.02 Non-Reliance on Previously Issued Financial Statements
On
June 18, 2018, the Audit Committee of the Board of Directors (the “
Audit Committee
”) was advised by the Company’s
independent registered public accounting firm, Morison Cogen LLP (“
Morison
”), that the following previously
filed financial statements of the Company should not be relied upon:
|
(i)
|
The
Company’s audited consolidated financial statements for the fiscal year ended December 31, 2017, contained in the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2017, originally filed with the Securities and Exchange
Commission (“
SEC
”) on April 3, 2018 (the “
Annual Report
”),
|
|
|
|
|
(ii)
|
The
Company’s unaudited financial statement for the quarterly period ended September 30, 2017, contained in the Company’s
Quarterly Report on Form 10-Q, originally filed with the SEC on November 14, 2017 (the “
Q3 Report
”); and
|
|
|
|
|
(iii)
|
The
Company’s unaudited financial statement for the quarterly period ended June 30, 2017, contained in the Company’s
Quarterly Report on Form 10-Q, originally filed with the SEC on August 14, 2017 (the “
Q2 Report
”, which
along with the Q3 Report and the Annual Report are referred to herein as the “
Reports
”).
|
Subsequent
to the filing of the Annual Report certain information came to the attention of the Audit Committee that certain 2017 revenue
transactions did not qualify for revenue recognition under generally accepted accounting principles. The Audit Committee is overseeing
an investigation of these matters with assistance of Morison, outside counsel and forensic accountants.
The
Company will, as soon as is practicable, make the appropriate adjustments to the above referenced Reports by filing with the SEC
amendments to the Reports which, in each case, will include restated consolidated financial statements and notes thereto and any
other appropriate revisions.
The
Company’s Audit Committee discussed the matters described in this Item 4.02 with representatives of Morison. In accordance
with Item 4.02(c) of Form 8-K, the Company provided Morison with a copy of the statements set forth in this Item 4.02 prior to
the filing of this Report with the SEC. The Company requested that Morison furnish the Company with a letter addressed to the
SEC stating whether Morison agrees with the above statements in this Item 4.02 as required by SEC rules. Morison has furnished
the requested letter, and it is attached as an Exhibit 7.1 to this Report.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
Cautionary
Note Regarding Forward-Looking Statements
This
Current Report on Form 8-K, the press release included herein, and any statements of representatives and partners of the Company
related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties.
Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections,
expectations and intentions and other statements identified by words such as “projects,” “may,” “will,”
“could,” “would,” “should,” “believes,” “expects,” “anticipates,”
“estimates,” “intends,” “plans,” “potential” or similar expressions. These statements
are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and
uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results
(including, without limitation the timing for and results of the Company’s pending restatement, including the actual amounts
deferred and recognized once such amounts are subject to audit) may differ significantly from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company’s control). The Company undertakes no obligation to
publicly
update
any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable
law.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS
BIOSCIENCES, INC.
|
|
|
|
Date:
June 19, 2018
|
By:
|
/s/
John J. Gormally
|
|
|
John
J. Gormally
|
|
|
Chief
Executive Officer
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Akers Biosciences Inc (NASDAQ): 0 recent articles
More Akers Biosciences, Inc. News Articles